Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials

References

• Mm W, Deodhar A, Gensler LS, et al. Update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken). 2019 Oct;71(10):1599–1613.
   PubMed Web of Science ®Google Scholar
• Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018;7.
   PubMedGoogle Scholar
• Deodhar A, Chakravarty SD, Cameron C, et al. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020 Aug;39(8):2307–2315.
   PubMed Web of Science ®Google Scholar
• Braun J, van Den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011 Jun;70(6):896–904.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Gerriets V, Bansal P, Goyal A, et al. Tumor necrosis factor inhibitors. statpearls. Treasure Island (FL): StatPearls Publishing; Copyright © 2021, StatPearls Publishing LLC. 2021.
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244–279.
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (review). Mol Med Rep. 2017 Apr;15(4):1943–1951.
   PubMed Web of Science ®Google Scholar
• Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheumatism. 1995 Apr;38(4):499–505.
   PubMed Web of Science ®Google Scholar
• François RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006 Jun;65(6):713–720.
   PubMed Web of Science ®Google Scholar
• Baeten D, Kruithof E, Van Den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheumatism. 2001 Jan;44(1):186–195.
   PubMedGoogle Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443–1453.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Infliximab: summary of product characteristics. [Cited 2021 Apr 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
   Google Scholar
• Van Den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheumatism. 2002 Mar;46(3):755–765.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (London, England). 2002 Apr 6;359(9313):1187–93.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis and rheumatism. 2003 Aug;48(8):2224–33.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005 Feb;64(2):229–234.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford). 2005 May;44(5):670–676.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008 Mar;64(3):340–345.
   Google Scholar
• Pérez-Guijo VC, Cravo AR, Castro Mdel C, et al. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):254–258.
   PubMed Web of Science ®Google Scholar
• Li EK, Griffith JF, Lee VW, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford). 2008 Sep;47(9):1358–1363.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheumatism. 1998 Sep;41(9):1552–1563.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007 Sep;46(9):1450–1453.
   PubMed Web of Science ®Google Scholar
• Creemers MC, Franssen MJ, Ma VH, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005 Jan;64(1):127–129.
   PubMed Web of Science ®Google Scholar
• Spoorenberg A, de Vlam K, van der Heijde D, et al. Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol. 1999 Apr;26(4):997–1002.
   PubMed Web of Science ®Google Scholar
• Braun J, Landewé R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheumatism. 2006 May;54(5):1646–1652.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheumatism. 2003 Apr;48(4):1126–1136.
   PubMed Web of Science ®Google Scholar
• Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005 Dec;44(12):1525–1530.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Etanercept: summary of product characteristics. [cited 2021 Apr 16. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel
   Google Scholar
• Davis J Jr., Webb A, Lund S, et al. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheumatism. 2004 Apr 15;51(2):302–304.
   PubMedGoogle Scholar
• Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheumatism. 2001 Aug;44(8):1876–1886.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dougados M, Davis J, et al. ASsessment in ankylosing spondylitis international working group/spondylitis association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheumatism. 2005 Feb;52(2):386–394.
   PubMedGoogle Scholar
• Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheumatism. 2003 Jun;48(6):1667–1675.
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005 Mar;44(3):342–348.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheumatism. 2005 Dec 15;53(6):856–863.
   PubMedGoogle Scholar
• Baraliakos X, Haibel H, Fritz C, et al., Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15(3): R67.
   PubMed Web of Science ®Google Scholar
• Rios RV, Kg H, Weiß A, et al. Progression of structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during long-term anti-tumor necrosis factor treatment: six-year results of continuous treatment with etanercept. Arthritis Rheumatol (Hoboken). 2019 May;71(5):722–728.
   PubMed Web of Science ®Google Scholar
• Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004 Dec;63(12):1594–1600.
   PubMed Web of Science ®Google Scholar
• Song IH Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011 Apr;70(4):590–596.
   PubMed Web of Science ®Google Scholar
• Song IH Hermann KG Haibel H, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis. 2011 Jul;70(7):1257–1263.
   PubMed Web of Science ®Google Scholar
• Song IH Hermann KG Haibel H, et al. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology (Oxford). 2015 Feb;54(2):257–261.
   PubMed Web of Science ®Google Scholar
• Song IH Hermann KG Haibel H, et al. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis–3-Year data of the ESTHER trial. Semin Arthritis Rheum. 2016 Feb;45(4):404–410.
   PubMed Web of Science ®Google Scholar
• Song IH Hermann KG Haibel H, et al. Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014 Oct;41(10):2034–2040.
   PubMed Web of Science ®Google Scholar
• Proft F, Weiß A, Torgutalp M, et al. Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. Ther Adv Musculoskelet Dis. 2021;13:1759720x20987700.
   Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheumatism. 2008 May;58(5):1324–1331.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism. 2006 Jul;54(7):2136–2146.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Adalimumab: summary of product characteristics. [cited 2021 May 4]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
   Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheumatism. 2008 Jul;58(7):1981–1991.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Breban M, Halter D, et al. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford). 2015 Jul;54(7):1210–1219.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Hc B, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheumatism. 2006 Feb;54(2):678–681.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Poddubnyy D, Sørensen IJ, et al. Course of magnetic resonance imaging-detected inflammation and structural lesions in the sacroiliac joints of patients in the randomized, double-blind, placebo-controlled danish multicenter study of adalimumab in spondyloarthritis, as assessed by the Berlin and spondyloarthritis research consortium of canada methods. Arthritis Rheumatol (Hoboken). 2016 Feb;68(2):418–429.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014 Jun;74(9):999–1016.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Certolizumab: summary of product characteristics. [cited 2021 May 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf
   Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014 Jan;73(1):39–47.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017 Sep 1;56(9):1498–1509.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Hermann KA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018 May;77(5):699–705.
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228–233.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890–1896.
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. mAbs. 2010 Jul-Aug;2(4):428–439.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Golimumab: summary of product characteristics. [cited 2021 May 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf
   Google Scholar
• US Food and drug administration. Simponi: highlights of prescribing information. [cited 2021 Sept 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125433s030s031lbl.pdf
   Google Scholar
• Inman RD, Davis JC Jr., Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheumatism. 2008 Nov;58(11):3402–3412.
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012 May;71(5):661–667.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015 Apr;74(4):757–761.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014 Jun;73(6):1107–1113.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012 Jun;71(6):878–884.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Reveille JD, Harrison DD, et al. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the Go-Alive study. J Rheumatol. 2018 Mar;45(3):341–348.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Deodhar A, Caldron PH, et al. Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study. J Rheumatol. 2019 Oct;46(10):1277–1283.
   PubMed Web of Science ®Google Scholar
• Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017 Sep;76(9):1515–1521.
   PubMed Web of Science ®Google Scholar
• van der Horst-bruinsma I, van Bentum R, Verbraak FD, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020 Apr;6:1.
   Web of Science ®Google Scholar
• van Bentum RE, Heslinga SC, Nurmohamed MT, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY study. J Rheumatol. 2019 Feb;46(2):153–159.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheumatism. 2005 Aug;52(8):2447–2451.
   PubMed Web of Science ®Google Scholar
• Choi EY, Lee M, Lee CS. Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients. Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1132–1137.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Jan;74(1):65–73.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2021 Apr 19;4(4):Cd011535.
   PubMedGoogle Scholar
• Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheumatism. 2005 Aug;52(8):2513–2518.
   PubMedGoogle Scholar
• Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16(1):19.
   PubMed Web of Science ®Google Scholar
• Pantavou K, Yiallourou AI, Piovani D, et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: a systematic overview of meta-analyses. United European Gastroenterol J. 2019 Dec;7(10):1285–1303.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May;45(10):1291–1302.
   PubMed Web of Science ®Google Scholar
• Kim HA, Lee E, Lee SK, et al. Efficacy of the biosimilar CT-P13 versus reference infliximab in patients with ankylosing spondylitis: a propensity score-matched analysis from the Korean college of rheumatology biologics registry. BioDrugs. 2020 Aug;34(4):529–539.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013 Oct;72(10):1605–1612.
   PubMed Web of Science ®Google Scholar
• Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021 Mar;8(1):41–61.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017 Dec 1;56(12):2093–2101.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017 Apr;176(4):928–938.
   PubMed Web of Science ®Google Scholar
• Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PloS One. 2017;12(4):e0175207.
   PubMed Web of Science ®Google Scholar
• Gehin JE, Goll GL, Warren DJ, et al. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. Arthritis Res Ther. 2019 Nov 29;21(1):256.
   PubMed Web of Science ®Google Scholar
• Gehin JE, Warren DJ, Syversen SW, et al. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scand J Rheumatol. 2021;2:1–10.
   Google Scholar
• Balsa A, Sanmarti R, Rosas J, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018 Apr 1;57(4):688–693.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Rispens T, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020 Jan;6(1). https://doi.org/10.1136/rmdopen-2019-001047.
   Google Scholar
• Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005 Oct;64(10):1462–1466.
   PubMed Web of Science ®Google Scholar
• Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the swiss clinical quality management cohort. Ann Rheum Dis. 2018 Jan;77(1):63–69.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheumatism. 2012 May;64(5):1388–1398.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheumatism. 2013 Oct;65(10):2645–2654.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014 Feb;53(2):213–222.
   PubMed Web of Science ®Google Scholar
• Mirdamadi K, Salinas T, Vali R, et al. Meta-analysis of pregnancy outcomes after exposure to tnf-α inhibitors during pregnancy for the treatment of arthritic diseases. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique. 2018; Apr,;10 25(1):e53–e56. doi
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr;27.
   Google Scholar
• European Medicines Agency. Upadacitinib: summary of product characteristics. [cited 2021 Sept 6]. Available from: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf
   Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50–55.
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017 Mar;76(3):571–592.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016 Feb;75(2):408–412.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Secukinumab: summary of product characteristics. [cited 2021 Sept 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Ixekizumab: summary of product characteristics. [cited 2021 Sept 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
   Google Scholar
• Wei JC, Kim TH, Kishimoto M, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021 Apr;7.
   Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-rangin study. Ann Rheum Dis. 2020 May;79(5):595–604.
   PubMed Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Boonen A, Chorus A, Miedema H, et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of dutch patients. Ann Rheum Dis. 2001 Apr;60(4):353–358.
   PubMed Web of Science ®Google Scholar